(Health-NewsWire.Net, December 09, 2016 ) Bladder cancer occurs in tissues of the urinary bladder. Symptoms include blood or blood clots in the urine, frequent urination, lower back pain on one side of the body and burning during urination. Risk factors for bladder cancer include smoking, exposure to substances such as rubber, certain dyes and textiles, paint, and hairdressing supplies, diet rich in fried meats and fat, old age, sex and color, certain parasitic infections. Treatment of bladder cancer includes chemotherapy, surgery, biological therapy and radiation therapy. For more information about this report at http://www.reportsweb.com/bladder-cancer-pipeline-review-h2-2016 Report Highlights:
Publisher's Pharmaceutical and Healthcare latest pipeline guide Bladder Cancer - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Bladder Cancer (Oncology) , complete with analysis by stage of development, drug target, mechanism of action (MoA) , route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Bladder Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Bladder Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 9, 44, 35, 2, 56 and 12 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 3, 1, 12 and 2 molecules, respectively.Bladder Cancer.
Bladder Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Request a sample copy at http://www.reportsweb.com/inquiry&RW0001461479/sample Report Scope:
- The pipeline guide provides a snapshot of the global therapeutic landscape of Bladder Cancer (Oncology) . - The pipeline guide reviews pipeline therapeutics for Bladder Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Bladder Cancer (Oncology) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Bladder Cancer (Oncology) therapeutics based on mechanism of action (MoA) , drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Bladder Cancer (Oncology) Reasons to buy:
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Bladder Cancer (Oncology) . - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Bladder Cancer (Oncology) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline. Table of Contents: Introduction 7 Bladder Cancer Overview 8 Therapeutics Development 9 Bladder Cancer - Therapeutics under Development by Companies 11 Bladder Cancer - Therapeutics under Investigation by Universities/Institutes 19 Bladder Cancer - Pipeline Products Glance 20 Bladder Cancer - Products under Development by Companies 23 Bladder Cancer - Products under Investigation by Universities/Institutes 34 Bladder Cancer - Companies Involved in Therapeutics Development 35 Bladder Cancer - Therapeutics Assessment 144 Drug Profiles 167 Bladder Cancer - Dormant Projects 693 Bladder Cancer - Discontinued Products 703 Bladder Cancer - Product Development Milestones 704 Appendix 721 Ask for Discount at http://www.reportsweb.com/inquiry&RW0001461479/discount List of Tables: Number of Products under Development for Bladder Cancer, H2 2016 29 Number of Products under Development for Bladder Cancer - Comparative Analysis, H2 2016 30 Number of Products under Development by Companies, H2 2016 31 Number of Products under Investigation by Universities/Institutes, H2 2016 39 Comparative Analysis by Late Stage Development, H2 2016 40 Comparative Analysis by Clinical Stage Development, H2 2016 41 Comparative Analysis by Early Stage Products, H2 2016 42 Assessment by Monotherapy Products, H2 2016 164 Assessment by Combination Products, H2 2016 165 Number of Products by Top 10 Targets, H2 2016 166 Number of Products by Stage and Top 10 Targets, H2 2016 166 Number of Products by Top 10 Mechanism of Actions, H2 2016 174 Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 174 Number of Products by Top 10 Routes of Administration, H2 2016 183 Number of Products by Stage and Top 10 Routes of Administration, H2 2016 183 Number of Products by Top 10 Molecule Types, H2 2016 185 Number of Products by Stage and Top 10 Molecule Types, H2 2016 185 Contact Us: Call: +1-646-491-9876 Email: sales@reportsweb.com
ReportsWeb.com
Priya Sisodia
+1-646-491-9876
sales@reportsweb.com
Source: EmailWire.Com
|